Surgical Treatment and Chemotherapy of Adult Primary Liver Sarcoma: Experiences from a Single Hospital in China

Abstract

Background: The aim of this study is to improve the preoperative diagnostic accuracy and treatment results by investigating the clinical features and prognosis of primary liver sarcoma (PLS). Methods: Clinical data, surgical treatments, adjuvant chemotherapy, and prognosis of 17 PLS patients whose diseases were pathologically confirmed were retrospectively analyzed. Results: The main clinical symptoms included epigastric pain in 9 patients, epigastric distention in 7, and loss of appetite in 4; these symptoms were detected during the postoperative follow-up for gastric carcinoma in 1. The resection rate was 64.7% (12/17), including R0 resection in 10 patients and R1 resection in 2, and laparotomy with biopsy in 5. Five patients accepted an adjuvant selective hepatic artery infusion chemotherapy (mitomycin C 16–20 mg+ 5-fluorouracil 5.0 g+ epirubicin 40–50 mg), and 4 accepted adjuvant systemic chemotherapy (vincristin, cisplatin, cyclophosphamide, and adriamycin). All 5 patients with simple laparotomy died within 1 year, and the overall 1-, 3-, and 5-year survival rates for all patients were 58.8% (10/17), 29.4% (5/17) and 11.7% (2/17), respectively, whereas those were 100.0% (10/10), 50.0% (5/10), and 20.0% (2/10) for R0 resected patients respectively. Conclusions: The diagnosis of PLS is difficult before operation due to its nonspecific manifestations, and the high survival rate can be achieved by radical resection with adjuvant chemotherapy.

Ultrasonography, contrast-enhanced ultrasonography and contrast- enhanced computer tomography features of hepatic sarcomatoid carcinoma and hepatic sarcoma: a retrospective study of 23 cases

“…In the venous phase, the degree of enhancement started to drop signi cantly, with uneven enhancement or brim enhancement and no central necrosis. This contradicts a recent summary of a retrospective study of 14 patients with HSC, which found that CECT revealed progressive or persistent heterogeneous enhancement, as well as central necrosis [30] . This could be due to the small number of patients in our HSC group who underwent CECT.…”

“…They are unusual, featured with nonspeci c symptoms, and often present asymptomatic until they have become large, leading to a clinical dilemma. Clinically, asymptomatic, epigastric pain, bloating, anorexia, fatigue and weight loss are main symptoms of these two liver tumors [11][12][13][14] . It has been reported that HSC and HS are initially misdiagnosed as hepatic abscess, HCC, and malignant tumor (MT) by imaging [15][16][17][18] .…”

A prognostic 3‐long noncoding RNA signature for patients with gastric cancer

“…The poor prognosis of GC is mainly decided by local and systemic metastasis . Surgery is the most effective treatment for resectable gastric cancer . Despite the recent therapeutic advances, the overall long‐term outcomes of GC remain poor.…”

“…2 Surgery is the most effective treatment for resectable gastric cancer. 2,3 Despite the recent therapeutic advances, the overall long-term outcomes of GC remain poor. The TNM staging system, which is developed by American Joint Committee on Cancer (AJCC), provides a useful benchmark for prognostic prediction and establishment of treatment strategy.…”

Efficacy and Safety of Trans-Arterial Yttrium-90 Radioembolization in Patients with Unresectable Liver-Dominant Metastatic or Primary Hepatic Soft Tissue Sarcomas

“…However, many patients have unresectable disease or are not surgical candidates due to poor performance status or comorbidities. For these patients, systemic chemotherapy is employed treatment although response rates are low [ 15 , 16 , 17 ]. Thus, localized transcatheter liver-directed therapies (LDTs), including trans-arterial chemoembolization (TACE), bland embolization (TABE), and Yttrium-90 (Y90) radioembolization (TARE), offer a valuable treatment alternative for these patients.…”